Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison

View Full Paper
Ask AI
Bookmark
Share

Authors

LNLay She Ng

Discussion

Loading...

Member takes

Overview

Retrospective cohort study found zanubrutinib reduced adverse events in chronic lymphocytic leukemia, indicating a safer option for treatment.

Key Points

  • Zanubrutinib showed lower rates of fatal hemorrhage and infections compared to acalabrutinib.
  • Patients using zanubrutinib experienced fewer cytopenias and cardiotoxicity events, suggesting a preferable safety profile.
  • Propensity score matching ensured balanced baseline characteristics between treatment groups during analysis.
  • Longer treatment discontinuation time indicates better tolerability with zanubrutinib, emphasizing its potential as a preferred BTKi.

Cite This Study

Lay She Ng (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbf8https://doi.org/10.1182/blood-2025-7419
View Full Paper
Ask AI
Bookmark
Share